Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (NVS)
NYSE:NVS
Holding NVS?
Track your performance easily
NVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$92.35 - $120.92
Previous Close$98.36
Volume1.26M
Average Volume (3M)1.11M
Market Cap
$194.96B
Enterprise Value$200.88B
Total Cash (Recent Filing)$14.43B
Total Debt (Recent Filing)$20.26B
Price to Earnings (P/E)11.4
Beta0.49
Next Earnings
Jan 31, 2025EPS Estimate
$1.83Last Dividend Ex-Date
Mar 07, 2024Dividend Yield3.25%
Share Statistics
EPS (TTM)8.63
Shares Outstanding2,044,033,986
10 Day Avg. Volume1,087,844
30 Day Avg. Volume1,110,675
Standard Deviation0.06
R-Squared0.26
Alpha0.00018
Financial Highlights & Ratios
Price to Book (P/B)4.31
Price to Sales (P/S)4.31
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.75
Enterprise Value/Gross Profit5.88
Enterprise Value/Ebitda24.48
Forecast
1Y Price Target
$140.50Price Target Upside43.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Novartis News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Long-term GrowthNVS is well-positioned for long-term growth despite above-consensus product sales growth through management’s mid-term guidance timeframe.
Product ApprovalCosentyx is expected to grow further with the approval of the HS indication and IV formulation.
Bears Say
Portfolio DecisionsManagement noted that IRA-related price cuts appear manageable but also noted that the 9-year price setting for small molecules vs the 13-year price setting for biologics is an issue that potentially impacts portfolio decisions.
Portfolio StrategyManagement noted that IRA-related price cuts appear manageable but also noted that the 9-year price setting for small molecules vs the 13-year price setting for biologics is an issue that potentially impacts portfolio decisions in favor of biologics.
Stock ValuationThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
---
Ownership Overview
―
Insiders
1.70% Mutual Funds
2.80% Other Institutional Investors
95.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVS FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest stock price was $92.35 and its highest was $120.92 in the past 12 months.
What is Novartis Ag’s market cap?
Currently, no data Available
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Jan 31, 2025 which is in 41 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Oct 29, 2024. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.938 by $0.122.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Undervalued.
Does Novartis Ag pay dividends?
Novartis Ag pays a Annually dividend of $2.455 which represents an annual dividend yield of 3.25%. See more information on Novartis Ag dividends here
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is $1.83.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,189,930,400 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $2.06 in its last earnings report, beating expectations of $1.938. Following the earnings report the stock price went down -4.411%.
Which hedge fund is a major shareholder of Novartis Ag?
Among the largest hedge funds holding Novartis Ag’s share is Dodge & Cox. It holds Novartis Ag’s shares valued at 1B.
---
Novartis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$140.50 (43.70% Upside)
$140.50 (43.70% Upside)
Blogger Sentiment
Bullish
NVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 92.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.06%
12-Months-Change
Fundamentals
Return on Equity
28.87%
Trailing 12-Months
Asset Growth
-8.14%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG develops, manufactures and sells healthcare products. Its two reporting segments are: Innovative Medicines and Sandoz. The Innovative Medicines business develops and sells patented prescription medicines and is made up of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
---
NVS Company Deck
---
NVS Earnings Call
Q3 2024
0:00 / 0:00
---
NVS Stock 12 Month Forecast
Average Price Target
$140.50
▲(43.70% Upside)
Technical Analysis
Best Analysts Covering NVS
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-5.00%
reiterated a buy rating 27 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.00% per trade.
---